Rigel surges as FDA waives pan­el; Trou­bled En­do­cyte looks for come­back fol­low­ing $12M li­cens­ing deal; Seat­tle Ge­net­ics scores a ‘break­through’

→ Shares of Rigel Ther­a­peu­tics $RIGL bound­ed up about 20% this morn­ing af­ter the biotech re­port­ed that the FDA has no plans to call an ex­pert pan­el to­geth­er to re­view fos­ta­ma­tinib in pa­tients with chron­ic or per­sis­tent im­mune throm­bo­cy­tope­nia. The FDA al­so has in­di­cat­ed that it ex­pects to hit its April 17, 2018, PDU­FA dead­line for a de­ci­sion. There are no guar­an­tees, of course, but that’s all gen­er­al­ly con­sid­ered pos­i­tive.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.